Mapi Research Trust appointed as exclusive distributor and Mapi Language Services as exclusive translator of the "Disease Activity Score (DAS-28)"

The Disease Activity Score (DAS-28) was developed by Piet Van Riel and aims at following and predicting disease activity in patients with rheumatoid arthritis (RA). Since its publication in Prevoo et al., Arthritis Rheum in 1995, it has become a reference tool used in almost every clinical practice and clinical research projects in RA. It includes swollen and tender joint counts, assessment of disease activity and erythrocyte sedimentation rate (ESR), providing a 0-10 disease activity score.

"Collaborating with Mapi will lead to the production of high quality and harmonized translations and electronic versions of the DAS-28 and their dissemination within the scientific community, while respecting the integrity of the original instrument," said Piet van Riel.

"The distribution of the DAS-28 by Mapi Research Trust will facilitate the access to the official original questionnaire and all its derivatives such as translations and electronic versions through an easy and controlled access," said Katrin Conway, Managing Director of the Mapi Research Trust. "The DAS-28, largely used both in clinical research and practice for twenty years, deserves the highest linguistic validation and electronic migration standards established by Mapi, for the benefit of the whole scientific community," added Ana Bayles, Global Director – Mapi Language Services.

Mapi is organizing an author webinar on the DAS-28 on July 13rd during which Prof Dr Piet van Riel will present the instrument and its advantages for clinical practice and research. To register for free to this webinar, please consult http://mapigroup.com/eventcalendar/author-webinar-disease-activity-score-das-28/

For any request about the DAS-28 or to view the DAS-28's description, please consult https://eprovide.mapi-trust.org/

About Mapi Language Services:

Mapi Language Services is the worldwide leader in medical translation and Linguistic Validation of COAs for nearly 3 decades. Mapi has first-hand knowledge of local languages and cultures, regulations, and healthcare practices. We work in close collaboration with developers, assure conceptual equivalence and international harmonization of all language versions. Mapi Language Services' experience represents more than 40,000 translated versions of 2,500 Questionnaires in 170 languages.  Visit http://www.mapigroup.com for more information.

About Mapi Research Trust:

Mapi Research Trust is a Non-Profit arm of Mapi Group and works in collaboration with Academic Researchers, Life-Science Companies and Regulatory bodies. It is the largest curator of Clinical Outcomes Assessments (COA) and their translations, the largest single COA licensing provider and the most trusted name in distribution of COA instruments exclusively representing over 300 questionnaires.  Visit http://mapi-trust.org/ for more information.

About Pr Dr Piet van Riel: 

Professor Dr Piet van Riel is Rheumatologist at the Radboud University Nijmegen, the Netherlands. Some of his current activities are President of the DREAM-RA registry and practicing rheumatologist at Bernhoven, Uden, The Netherlands. 

Prof Dr van Riel is an active member of many professional societies, including the Dutch Society of Rheumatology, of which he was Chairman from 2003 up to 2009, the American College of Rheumatology and the British Society of Rheumatology. From 1999 to 2003 he was Chairman of the EULAR Standing Committee for International Clinical Studies Including Therapeutic Trials.

Prof Dr van Riel's research interests include clinical research in rheumatology, clinical pharmacology and clinimetrics.  He is on the editorial board of a number of journals, and has authored or co-authored several books and over 700 international publications.

Press contact: [email protected]

SOURCE Mapi Research Trust

Related Links

http://www.mapigroup.com